Comparing the current results to its competitors, Ideaya Biosciences Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Ideaya Biosciences Inc 's competitors' average revenue growth of 13.5 %, achieved in the same quarter.
Ideaya Biosciences Inc , slower than the average decrease reported by the company's competitors of -9.23 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -9.23 %
Ideaya Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology industry, which is characterized by competition and technological innovation. It faces risks including the development of new technologies by competitors, protection of proprietary technology, reliance on key personnel and partners, regulatory compliance, and the need for additional financing. Its product candidates require extensive research, clinical trials, regulatory approval, capital investment, personnel, and compliance efforts prior to commercialization.
August 1, 2024
IDEAYA Biosciences Advances Cancer Therapeutics with B7H3/PTK7-ADCIDEAYA Biosciences, Inc. (Nasdaq: IDYA) is making significant strides in the field of cancer therapeutics with its latest development of the B7H3/PTK7 antibody-drug conjugate (ADC), identified as ADC02315. This progressive approach leverages targeted therapy mechanisms to improve treatment outcomes for patients with hard-to-treat cancers.The B7H3/PTK7 ADC represents a fusion of two promising targets: B7H3, a well-characterized immune checkpoint protein frequently expressed in various malignancies, and PTK7, a surface protein associated with tumor development and progression. By strategically combining these targets, IDEAYA aims to enhance the...
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Ideaya Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ideaya Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
